Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00253513 · OUTCOME

Number of Patients Experiencing Graft Failure

Treosulfan and Fludarabine in Treating Younger Patients Who Are Undergoing a Donor Stem Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome · Source last updated 2012-06-01

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
participants
Interval / dispersion
Not reported
Time frame
42 days

What was measured

Graft versus Host Disease (GVHD) is a frequent complication of allogeneic bone marrow transplant in which the engrafted donor cells attacks the patient's organs and tissue. Acute GVHD (aGVHD) usually occurs during the first three months following an allogeneic BMT. Chronic GVHD (cGVHD) usually develops after the third month post-transplant. Patients may experience one, both or neither.

Analysis population: For graft failure 2 of the 60 patients were not evaluable because they exeperienced another event (relapsed) before they could be evaluable for graft failure.

Groups in this outcome

Treosulfan and Fludarabine Conditioning

Conditioning with Treosulfan (12 or 14 g/m2, IV for 5 days) and Fludarabine (30 mg/m2, IV for 5 days) followed by Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Treosulfan and Fludarabine Conditioning58

Reported measurements

acute graft vs. host disease (aGVHD)
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Treosulfan and Fludarabine Conditioning36Not reportedNot reportedNot reportedNot reported
chronic graft vs. host disease (cGVHD)
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Treosulfan and Fludarabine Conditioning31Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        36
    title
    acute graft vs. host disease (aGVHD)
  2. categories
    1. measurements
      1. group Id
        OG000
        value
        31
    title
    chronic graft vs. host disease (cGVHD)
denoms
  1. counts
    1. group Id
      OG000
      value
      58
    units
    Participants
description
Graft versus Host Disease (GVHD) is a frequent complication of allogeneic bone marrow transplant in which the engrafted donor cells attacks the patient's organs and tissue. Acute GVHD (aGVHD) usually occurs during the first three months following an allogeneic BMT. Chronic GVHD (cGVHD) usually develops after the third month post-transplant. Patients may experience one, both or neither.
groups
  1. description
    Conditioning with Treosulfan (12 or 14 g/m2, IV for 5 days) and Fludarabine (30 mg/m2, IV for 5 days) followed by Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies
    id
    OG000
    title
    Treosulfan and Fludarabine Conditioning
param Type
NUMBER
population Description
For graft failure 2 of the 60 patients were not evaluable because they exeperienced another event (relapsed) before they could be evaluable for graft failure.
reporting Status
POSTED
time Frame
42 days
title
Number of Patients Experiencing Graft Failure
type
PRIMARY
unit Of Measure
participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice